The NTCC? GBM39 cell line is a human patient-derived xenograft (PDX) model for glioblastoma (GBM). It's a type of cancer cell line that is particularly valuable in research because it closely mimics the characteristics of a patient's tumor, providing a more clinically relevant model than older, established cell lines.

Key Characteristics

• Origin: GBM39 was derived from a primary glioblastoma tumor in a 51-year-old male patient.

• Genetics: The cell line has a specific genetic profile that is important for research. It harbors the EGFRvIII (epidermal growth factor receptor variant III) mutation, a common alteration in glioblastoma that promotes tumor growth and is often resistant to treatment. It also has a methylated TERT promoter and amplification of MDM4 and PIK32B.

• Culture: It's typically cultured as floating cellular spheres (spheroids) in a specialized, serum-free medium to maintain its stem-cell-like properties and prevent differentiation. This mimics the in-vivo behavior of glioblastoma.

• Heterogeneity: The GBM39 line is not entirely uniform. It has a mix of cells, with about 90% having EGFR amplicons on extrachromosomal DNA (ecDNA) and the remaining 10% having them on homogeneously staining regions (HSRs). This heterogeneity makes it a good model for studying the different cellular populations within a real tumor.

Research Applications

The GBM39 cell line is a crucial tool for glioblastoma research, especially in the following areas:

• Preclinical Drug Discovery: Researchers use it to test the effectiveness of new therapies against glioblastoma. Its patient-like characteristics help in predicting how a drug might perform in a clinical setting.

• Therapy Resistance: Because it's derived from a difficult-to-treat cancer, GBM39 is used to study the mechanisms of resistance to standard therapies like temozolomide (TMZ) and radiation.

• Tumor Biology: Scientists study this cell line to better understand the fundamental biology of glioblastoma, including how the EGFRvIII mutation contributes to tumor growth, the role of extrachromosomal DNA in cancer, and the interactions between tumor cells and their microenvironment.

GBM39 細(xì)胞系是一種用于膠質(zhì)母細(xì)胞瘤（Glioblastoma, GBM）研究的人源患者腫瘤異種移植（Patient-Derived Xenograft, PDX）模型。這種癌細(xì)胞系在研究中非常有價(jià)值，因?yàn)樗芨叨饶M患者體內(nèi)腫瘤的特征，相比傳統(tǒng)的、已建立的細(xì)胞系，它提供了更具臨床相關(guān)性的模型。

主要特點(diǎn)

• 來(lái)源: GBM39 細(xì)胞系是從一名51歲男性患者的原發(fā)性膠質(zhì)母細(xì)胞瘤腫瘤中分離建立的。

• 遺傳學(xué): 該細(xì)胞系具有特定的遺傳圖譜，這對(duì)研究至關(guān)重要。它攜帶 EGFRvIII（表皮生長(zhǎng)因子受體 III 型變體）突變，這是膠質(zhì)母細(xì)胞瘤中常見(jiàn)的變異，它能促進(jìn)腫瘤生長(zhǎng)，并常導(dǎo)致對(duì)治療產(chǎn)生耐藥性。此外，它還具有甲基化的TERT啟動(dòng)子，以及MDM4和PIK32B的擴(kuò)增。

• 培養(yǎng)方式: 該細(xì)胞系通常在特殊的無(wú)血清培養(yǎng)基中以漂浮的細(xì)胞球（spheroids）形式進(jìn)行培養(yǎng)，以維持其干細(xì)胞樣的特性并防止分化。這種培養(yǎng)方式模擬了膠質(zhì)母細(xì)胞瘤在體內(nèi)的生長(zhǎng)行為。

• 異質(zhì)性: GBM39 細(xì)胞系并非完全同質(zhì)。它包含多種細(xì)胞，其中約90%的細(xì)胞在染色體外DNA（ecDNA）上具有EGFR擴(kuò)增子，而剩余的10%則位于均質(zhì)著色區(qū)（HSRs）上。這種異質(zhì)性使其成為研究真實(shí)腫瘤內(nèi)不同細(xì)胞群體的良好模型。

BioVector NTCC質(zhì)粒載體菌種細(xì)胞基因保藏中心

www.nedfriskphoto.com